← Human Trials & Peer-Reviewed Studies
Improvement of delivery and live birth rates after ICSI in women aged >40 years by ovarian co-stimulation with growth hormone.
Plain-language guide to PMID 15860489 (2005): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 15860489
- Journal
- Human reproduction (Oxford, England)
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Tesarik J et al. (3 authors)
- DOI
- 10.1093/humrep/dei066
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
Data on the use of exogenous GH in human assisted reproduction treatment are inconsistent.
This prospective randomized study evaluates the usefulness of GH administration in women of >40 years undergoing ovarian stimulation for assisted reproduction treatment.
Who Took Part
By PubMed's age tags, the people studied were adults, women only.
One hundred women of >40 years undergoing assisted reproduction treatment were randomized between a GH treatment group and a placebo group.
Assisted reproduction treatment outcomes were evaluated.
How the Study Was Run
In design terms this was a randomized and placebo-controlled study.
The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.
The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.
What Was Measured
This prospective randomized study evaluates the usefulness of GH administration in women of >40 years undergoing ovarian stimulation for assisted reproduction treatment.
The subject headings attached to it are Age Factors, Embryo Implantation, Human Growth Hormone, Oocytes, Ovarian Follicle, Ovulation Induction and Pregnancy Outcome.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2005 (Human reproduction (Oxford, England)), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.